Clinical trials awareness on a global level




















Distance 50 miles miles miles miles. Advanced Search. Researchers Search the database to stay up to date on developments in your field, find collaborators, and identify unmet needs. Study Record Managers Learn about registering studies and about submitting their results after study completion. National Library of Medicine U. National Institutes of Health U.

Department of Health and Human Services. Several studies indicate that awareness changes attitudes toward clinical trials, enrollment, and the benefits of participation. Harris Interactive Survey, In two separate studies, the Internet and general media were identified as the primary sources for learning about clinical trials ACRP, ; Taylor, Taylor, Health care providers play an important role in raising awareness about the option of clinical trial participation. By having a focused conversation about treatment options including clinical trials, a patient can be made aware of, and invited to enroll in a clinical research study.

Alvins A, Goldberg H. Creating a culture of research. Contemp Clin Trials. Public attitudes toward participation in cancer clinical trials. J Clin Oncol. A quantitative survey of public attitudes towards cancer clinical trials.

Physician-related factors involved in patient decisions to enroll onto cancer clinical trials. J Oncol Pract. Using geotargeting techniques, other new site locations may be identified. Stakeholders that support this network could invest in increased training and education among investigators and site staff, including supporting new sites in these underserved communities.

Those participating in the network would be able to share potential leading practices and learn from each other. Industry members within this network may also provide access to a consistent pipeline of research studies to create opportunities for investigators and sustain the network of ready clinical trial sites over time. Workshop participants and others who participated in our research identified steps the research clinical trial ecosystem should take to change the current paradigm and create a sustainable community-based infrastructure that is focused on clinical trial diversity, including:.

Elements of a community-based infrastructure supporting clinical trial diversity would include:. Discussions at the multistakeholder workshop concluded with recognition across the clinical trial ecosystem that a partnership to address clinical trial diversity is needed. A sustainable community-based partnership that begins well before clinical trials start can be essential to both building trust and creating a successful infrastructure that serves underrepresented populations.

Sustainability of the sites e. A toolbox of proven strategies of can minimize the need to reinvent the wheel with each new study or the current one-and-done clinical trial approach that results when a site is trained for a particular study but does not have a steady stream of additional studies following behind. Technology and data investments will be needed to measure and track progress moving forward. Many industry, health systems, academic institutions, government entities, patient advocacy, community leaders, technology experts, and CROs are working toward partnerships dedicated to enhancing clinical trial diversity through the formation of a sustainable, community-based clinical trial infrastructure.

Ultimately, investing in and supporting underserved communities can have a longer-term impact on the health and well-being of those communities beyond improving clinical trial diversity.

The in-depth report can be found here. The authors would first like to thank Pharmaceutical Research and Manufacturers of America PhRMA member companies who participated in interviews, the survey, and the workshop. The authors would also like to thank the many industry stakeholders who participated in interviews and the workshop.

This report would not be possible without their contributions. The authors would like to especially thank Dr. Freda Lewis-Hall for her guidance and insights throughout this research. This year-long collaboration required significant effort to execute research, analyze data, engage stakeholders, develop insights, and write, edit, and produce the report.

Life sciences companies continue to respond to a changing global landscape and strive to pursue innovative solutions to address today's challenges. Deloitte understands the complexity of these challenges and works with clients worldwide to drive progress and bring discoveries to life. Enhancing clinical trial diversity has been saved. Enhancing clinical trial diversity has been removed. An Article Titled Enhancing clinical trial diversity already exists in Saved items. To stay logged in, change your functional cookie settings.

Please enable JavaScript to view the site. Viewing offline content Limited functionality available. Article 13 minute read 11 November Enhancing clinical trial diversity.

Stakeholder perspectives on advancing research through representative clinical trials. Alexandria Younossi United States. Wendy Sanhai United States. Wendy Sanhai Specialist leader Dr.

Sonal Shah United States. Christine Chang United States. Jessica Overman United States. Email a customized link that shows your highlighted text. Copy a customized link that shows your highlighted text. Copy your highlighted text. Share by email. Opens in new window. Executive summary Clinical trial diversity is an imperative for health equity Racially and ethnically diverse clinical trial participants, representative of the intended patient population likely to use a medicine once approved, can help inform the safety and effectiveness evaluation of new medicines and the use of new medicines for patients.

Learn more Explore the life sciences collection Learn about Deloitte's services Go straight to smart. Get the Deloitte Insights app Opens in new window. Industry and ecosystem efforts have increased to address the challenge Enhancing meaningful representation of diverse participants in clinical trials would help provide information about drug response and measures of safety and efficacy in populations that have been historically underrepresented and understudied, Black and Latinx communities in particular.

Some examples include: The FDA issued draft guidance 3 on enhancing the diversity of clinical trial populations in the summer of and finalized the guidance in November Share image. Or copy link Copy. Ecosystem stakeholders recommend a path forward Shifting the paradigm will likely require substantial cross-stakeholder commitment and collaboration. Some possible collaborations include: Partnering with stakeholders across the clinical trial ecosystem patient groups, community members, clinical research sites, CROs, academia, nonprofit and advocacy organizations, federal and state agencies, industry, etc.

Workshop participants and others who participated in our research identified steps the research clinical trial ecosystem should take to change the current paradigm and create a sustainable community-based infrastructure that is focused on clinical trial diversity, including: Creating a network of clinical trial sites in underserved communities to make access easier so that those who want to participate can: Infrastructure stakeholders should develop research sites that meet potential participants where they already receive care, including nontraditional locations such as FQHCs or Catholic health systems.

These providers may be best positioned to engender trust and establish relationships with trusted messengers and leaders that are reflective of the cultural norms and demographics of the community, and with the right support and investment could be scaled into clinical trial sites in underserved communities.

Infrastructure efforts should consider and leverage—to the extent possible—any existing networks or structures involved in the conduct of clinical trials. It is critical for clinical trial sponsors to provide necessary funding and resources to sites and nontraditional locations that serve underrepresented populations. Establishing a pipeline of clinical trial opportunities can also be critical to help ensure continued engagement and commitment.

Establishing long-term relationships and investing in the community: It is critical to build long-lasting relationships rooted in a shared commitment to improve health equity in the communities being approached.



0コメント

  • 1000 / 1000